IL63890A0 - Improvements in or relating to 3-aryl-5-isothiazole derivatives - Google Patents

Improvements in or relating to 3-aryl-5-isothiazole derivatives

Info

Publication number
IL63890A0
IL63890A0 IL63890A IL6389081A IL63890A0 IL 63890 A0 IL63890 A0 IL 63890A0 IL 63890 A IL63890 A IL 63890A IL 6389081 A IL6389081 A IL 6389081A IL 63890 A0 IL63890 A0 IL 63890A0
Authority
IL
Israel
Prior art keywords
aryl
relating
isothiazole derivatives
isothiazole
derivatives
Prior art date
Application number
IL63890A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL63890A0 publication Critical patent/IL63890A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL63890A 1980-09-22 1981-09-20 Improvements in or relating to 3-aryl-5-isothiazole derivatives IL63890A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/189,435 US4346094A (en) 1980-09-22 1980-09-22 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels

Publications (1)

Publication Number Publication Date
IL63890A0 true IL63890A0 (en) 1981-12-31

Family

ID=22697314

Family Applications (1)

Application Number Title Priority Date Filing Date
IL63890A IL63890A0 (en) 1980-09-22 1981-09-20 Improvements in or relating to 3-aryl-5-isothiazole derivatives

Country Status (22)

Country Link
US (1) US4346094A (cs)
EP (1) EP0048615B1 (cs)
JP (1) JPS5785379A (cs)
KR (1) KR830007597A (cs)
AR (1) AR229103A1 (cs)
AT (1) ATE7657T1 (cs)
AU (1) AU7551681A (cs)
CS (1) CS228536B2 (cs)
DD (1) DD201790A5 (cs)
DE (1) DE3163900D1 (cs)
DK (1) DK417981A (cs)
ES (1) ES8301225A1 (cs)
FI (1) FI812940A7 (cs)
GB (1) GB2084573B (cs)
GR (1) GR75046B (cs)
IL (1) IL63890A0 (cs)
NO (1) NO813208L (cs)
PL (1) PL130497B1 (cs)
PT (1) PT73711B (cs)
RO (1) RO82216A (cs)
YU (1) YU227181A (cs)
ZA (1) ZA816549B (cs)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428956A (en) 1980-12-29 1984-01-31 Merck & Co., Inc. 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
US4431652A (en) * 1980-12-29 1984-02-14 Merck & Co., Inc. 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
US4539328A (en) * 1983-03-25 1985-09-03 Fmc Corporation Nematicidal isothiazole derivatives
US4620865A (en) * 1983-11-07 1986-11-04 Eli Lilly And Company Herbicidal and algicidal 1,5-disubstituted-1H-pyrazole-4-carboxamides
IE59813B1 (en) * 1986-05-09 1994-04-06 Warner Lambert Co Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
ZW21687A1 (en) * 1986-12-12 1988-07-20 Hoffmann La Roche Triazine derivatives
DK0513379T3 (da) * 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
US5294630A (en) * 1992-07-07 1994-03-15 Eli Lilly And Company Treatment of inflammatory bowel disease
US5436258A (en) * 1992-09-09 1995-07-25 Eli Lilly And Company Prevention of bone resorption
MY117352A (en) * 1995-10-31 2004-06-30 Ciba Sc Holding Ag Oximesulfonic acid esters and the use thereof as latent sulfonic acids.
ID21775A (id) * 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
US6191136B1 (en) 1997-11-07 2001-02-20 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
TW575792B (en) * 1998-08-19 2004-02-11 Ciba Sc Holding Ag New unsaturated oxime derivatives and the use thereof as latent acids
SG78412A1 (en) 1999-03-31 2001-02-20 Ciba Sc Holding Ag Oxime derivatives and the use thereof as latent acids
AU2003206787A1 (en) 2002-02-06 2003-09-02 Ciba Specialty Chemicals Holding Inc. Sulfonate derivatives and the use therof as latent acids
US7612108B2 (en) * 2004-08-27 2009-11-03 Astellas Pharma Inc. 2-phenylthiophene derivative
US7820700B2 (en) * 2004-08-27 2010-10-26 Astellas Pharma Inc. 2-phenylpyridine derivative
AU2006300422A1 (en) 2005-10-07 2007-04-19 Astellas Pharma Inc. Triarylcarboxylic acid derivative
CA2643272A1 (en) 2006-02-24 2007-08-30 Astellas Pharma Inc. Gent for treating or preventing digestive ulcer
GB2450975B (en) 2007-07-12 2010-02-24 Ciba Holding Inc Yellow radiation curing inks
JP5820269B2 (ja) * 2008-05-22 2015-11-24 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Sglt2阻害剤を使用する高尿酸血症の治療方法およびsglt2阻害剤を含有する組成物
JP5312570B2 (ja) 2009-02-27 2013-10-09 帝人ファーマ株式会社 遷移金属触媒を用いたカップリング法によるフェニル置換複素環誘導体の製造法
US20120043480A1 (en) 2009-03-30 2012-02-23 Basf Se Uv-dose indicator films
PL2610248T3 (pl) 2010-08-27 2016-12-30 Sposób wytwarzania podstawionych fenylem pochodnych heterocyklicznych metodą sprzęgania z użyciem związku palladu
WO2012101245A1 (en) 2011-01-28 2012-08-02 Basf Se Polymerizable composition comprising an oxime sulfonate as thermal curing agent
CA2904142A1 (en) 2013-03-29 2014-10-02 Teijin Pharma Limited Pyrazole derivative having a xanthine oxidase inhibitory activity
JP6664383B2 (ja) 2014-08-29 2020-03-13 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se オキシムスルホネート誘導体
CA2984044A1 (en) 2015-04-29 2016-11-03 Bsn Medical Gmbh Steady-state no production via ph control
US10813831B2 (en) 2015-04-29 2020-10-27 Bsn Medical Gmbh Medical bathing device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1178604A (en) * 1966-03-21 1970-01-21 American Cyanamid Co Novel Pyridinium Salts and Methods for Preparing Same
US3464999A (en) * 1967-07-27 1969-09-02 R & L Molecular Research Ltd Thiadiazolylisothiazoles
GB1180268A (en) * 1967-09-26 1970-02-04 Ici Ltd Pharmaceutically Active Phenyl-Heterocyclic-Alkanol Derivatives
GB1192701A (en) * 1968-03-22 1970-05-20 Ici Ltd Novel Thiazole Derivatives, the preparation thereof and Compositions containing the same
US3681498A (en) * 1970-10-19 1972-08-01 American Cyanamid Co Isothiazolyl pyridinium salts as hypoglycemic agents

Also Published As

Publication number Publication date
ES505678A0 (es) 1982-12-01
CS228536B2 (en) 1984-05-14
PL233103A1 (cs) 1982-12-20
ATE7657T1 (de) 1984-06-15
EP0048615A1 (en) 1982-03-31
PT73711A (en) 1981-10-01
GR75046B (cs) 1984-07-12
GB2084573A (en) 1982-04-15
DE3163900D1 (en) 1984-07-05
KR830007597A (ko) 1983-11-04
AR229103A1 (es) 1983-06-15
FI812940L (fi) 1982-03-23
GB2084573B (en) 1984-09-12
DD201790A5 (de) 1983-08-10
RO82216B (ro) 1983-06-30
ES8301225A1 (es) 1982-12-01
EP0048615B1 (en) 1984-05-30
DK417981A (da) 1982-03-23
US4346094A (en) 1982-08-24
YU227181A (en) 1983-10-31
PT73711B (en) 1982-12-20
RO82216A (ro) 1983-07-07
AU7551681A (en) 1982-04-01
ZA816549B (en) 1983-04-27
PL130497B1 (en) 1984-08-31
JPS5785379A (en) 1982-05-28
NO813208L (no) 1982-03-23
FI812940A7 (fi) 1982-03-23

Similar Documents

Publication Publication Date Title
EG15899A (en) Improvement in or relating to n-arybenzamide derivatives
DE3163900D1 (en) Improvements in or relating to 3-aryl-5-isothiazole derivatives
GB2117703B (en) Improvements in or relating to fire-barriers
DE3167442D1 (en) Improvements in or relating to cell lines
IL70075A0 (en) Improvements in or relating to 3-aryl-5-pyrazole derivatives
MY8700247A (en) Improvements in or relating to 2,4-disubtituted thiazole derivatives
GB2081945B (en) Improvements in or relating to carry circuits
GB2080062B (en) Improvements in or relating to amplifiers
ZA787058B (en) Improvements in or relating to plansifters
GB2119434B (en) Improvements in or relating to hinges
DE3169986D1 (en) Improvements in or relating to furnaces
GB2086964B (en) Improvements relating to shearer-loaders
PH15678A (en) Improvements in or relating to pyrazinobenzodiazepines
GB2109671B (en) Improvements in or relating to supports
PT72477A (en) Improvements in or relating to amino-fibres
GB2082997B (en) Improvements in or relating to conveyors
GB2102780B (en) Improvements in or relating to compounds
GB2145899B (en) Improvements in or relating to telecines
GB2100303B (en) Improvements in or relating to cardclothing
GB2300318B (en) Improvements in or relating to transceivers
GB2134577B (en) Improvements in or relating to roadsigns
PT74879A (en) Improvements in or relating to construction
GB2089135B (en) Improvements in or relating to baluns
GB2089107B (en) Improvements in or relating to laseres
GB2075347B (en) Improvements in or relating to catheters